However, the consulting panel says, FDA needs consideration whether it is a necessity to make a genetic test before Tamoxifen is prescribed to the postmenstrual women.

• 不过，顾问小组说，医生在为绝经后女性开具他莫西芬这种处方药时，是否必须先作基因测试，仍需药管局再作考虑。